Ultime notizie per PTC Therapeutics (NASDAQ:PTCT) Azioni

PTC THERAPEUTICS INC

PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

PTC Therapeutics Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Tycho Peterson upgraded the rating for GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) from Hold to Buy and announced a target of $80. GeneDx shares closed at $56.36 on Thursday. <a href="https://www.benzinga.com/quote/wgs/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Paul Lejuez upgraded the rating for National Vision Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) from Neutral to Buy and raised the price target from $13 to $21. National Vision shares closed at $16.68 on Thursday. <a href="https://www.benzinga.com/quote/eye/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Tazeen Ahmad upgraded PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Neutral to Buy and raised the price target from $55 to $68. PTC Therapeutics shares closed at $42.51 on Thursday. <a href="https://www.benzinga.com/quote/ptct/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying EYE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="614" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-1024x614.png" alt="" class="wp-image-910039" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-1024x614.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-768x460.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

News

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CVRX

PTCT

WOLF

This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday

B of A Securities analyst Tazeen Ahmad upgrades PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Neutral to Buy and raises the price target from $55 to $68.

Price Target

B of A Securities Upgrades PTC Therapeutics to Buy, Raises Price Target to $68

Barclays analyst Gena Wang maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Equal-Weight and lowers the price target from $56 to $42.

Barclays Maintains Equal-Weight on PTC Therapeutics, Lowers Price Target to $42

Baird analyst Joel Beatty maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Outperform and lowers the price target from $70 to $66.

Baird Maintains Outperform on PTC Therapeutics, Lowers Price Target to $66

RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Outperform and raises the price target from $57 to $58.

RBC Capital Maintains Outperform on PTC Therapeutics, Raises Price Target to $58

WIIM

PTC Therapeutics shares are trading higher after the company reported Q1 financial results and raised its FY25 sales guidance. Also, Citigroup upgraded its price target on the stock from Sell to Neutral.

Cantor Fitzgerald analyst Kristen Kluska maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and lowers the price target from $113 to $112.

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $112

JP Morgan analyst Eric Joseph maintains PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) with a Overweight and lowers the price target from $75 to $67.

JP Morgan Maintains Overweight on PTC Therapeutics, Lowers Price Target to $67

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler raised BlackLine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) price target from $46 to $50. Piper Sandler analyst Brent Bracelin maintained a Neutral rating. BlackLine shares closed at $46.65 on Tuesday. See how other <a href="https://www.benzinga.com/quote/BL/analyst-ratings">analysts view this stock</a>.</li>
<li>Telsey Advisory Group slashed the price target for Under Armour, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) from $10 to $7. Telsey Advisory Group analyst Cristina Fernandez maintained a Market Perform rating. Under Armour shares closed at $5.70 on Tuesday. <a href="https://www.benzinga.com/quote/UAA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Chardan Capital cut CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) price target from $84 to $82. Chardan Capital analyst Geulah Livshits maintained a Buy rating. CRISPR Therapeutics shares closed at $33.16 on Tuesday. <a href="https://www.benzinga.com/quote/CRSP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity slashed the price target for Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) from $150 to $145. Canaccord Genuity analyst Kingsley Crane maintained a Buy rating. Datadog shares closed at $106.06 on Tuesday. <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners raised the price target for Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) from $4 to $10. Leerink Partners analyst Marc Goodman upgraded the stock from Market Perform to Outperform. Amylyx Pharmaceuticals shares closed at $4.65 on Tuesday. See how other analysts view <a href="https://www.benzinga.com/quote/AMLX/analyst-ratings">this stock</a>.</li>
<li>Citigroup cut PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) price target from $50 to $40. Citigroup analyst Geoff Meacham upgraded the stock from Sell to Neutral. PTC Therapeutics shares settled at $36.19 on Tuesday. <a href="https://www.benzinga.com/quote/PTCT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt increased Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) price target from $85 to $94. Rosenblatt analyst Mike Genovese maintained a Buy rating. Lumentum shares closed at $64.42 on Tuesday. <a href="https://www.benzinga.com/quote/LITE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) price target from $145 to $130. Needham analyst Ryan Koontz maintained a Buy rating. Arista Networks shares closed at $90.77 on Tuesday.  <a href="https://www.benzinga.com/quote/ANET/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research raised the price target for Grand Canyon Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOPE#NASDAQ">LOPE</a>) from $205 to $215. Barrington Research analyst Alexander Paris maintained an Outperform rating. Grand Canyon Education shares settled at $185.45 on Tuesday. <a href="https://www.benzinga.com/quote/LOPE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity cut Qualys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) price target from $163 to $158. Canaccord Genuity analyst Michael Walkley maintained a Buy rating. Qualys shares closed at $126.82 on Tuesday. <a href="https://www.benzinga.com/quote/QLYS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying LITE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07080732/image-70-1024x585.png" alt="" class="wp-image-905454" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07080732/image-70-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07080732/image-70-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07080732/image-70-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07080732/image-70.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

ANET

CRSP

DDOG

LITE

LOPE

QLYS

Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Leerink Partners analyst Marc Goodman upgraded the rating for Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) from Market Perform to Outperform and raised the price target from $4 to $10. Amylyx Pharmaceuticals shares closed at $4.65 on Tuesday. <a href="https://www.benzinga.com/quote/amlx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Geoff Meacham upgraded PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Sell to Neutral but lowered the price target from $50 to $40. PTC Therapeutics shares closed at $36.19 on Tuesday. <a href="https://www.benzinga.com/quote/PTCT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Joern Iffert upgraded the rating for Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) from Neutral to Buy. Logitech International shares closed at $76.52 on Tuesday. <a href="https://www.benzinga.com/quote/LOGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barrington Research analyst James Goss upgraded CuriosityStream Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) from Market Perform to Outperform and announced a $6 price target. CuriosityStream shares closed at $3.30 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying LOGI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="627" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07074059/image-68-1024x627.png" alt="" class="wp-image-905410" style="width:560px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07074059/image-68-1024x627.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07074059/image-68-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07074059/image-68-768x470.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07074059/image-68.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

CURI

LOGI

RDDT

This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday

Citigroup analyst Geoff Meacham upgrades PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Sell to Neutral and lowers the price target from $50 to $40.

Citigroup Upgrades PTC Therapeutics to Neutral, Lowers Price Target to $40

PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) raises FY2025 sales outlook from $600.00 million-$800.00 million to $650.00 million-$800.00 million vs $720.13 million estimate.

Guidance

PTC Therapeutics Raises FY2025 Sales Guidance from $600.00M-$800.00M to $650.00M-$800.00M vs $720.13M Est

Earnings

Earnings Beats

PTC Therapeutics Q1 EPS $10.04, Sales $1.18B

<a href="https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics" title="https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics">https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics</a>

Biotech

General

BHVN

CAPR

DSGN

MRNA

NVAX

SLDB

SRPT

TSHA

XNCR

'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CVGI

CXDO

CYTK

DASH

DAWN

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Huntington&#8217;s disease (HD) patients</a>.
Huntington&#8217;s disease is&nbsp;a progressive neurodegenerative disorder caused by mutation of the&nbsp;huntingtin&nbsp;(HTT) gene, leading to the breakdown of brain cells.&nbsp;It is characterized by uncontrolled movements (chorea), cognitive decline, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45190339/ptc518-pivot-hd-study-achieves-primary-endpoint" rel="noreferrer noopener">and psychiatric disturbances</a>.
The study met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels (p&lt;0.0001) at Week 12 and favorable safety and tolerability. In addition, the 12-month data from the Stage 2 patients are consistent with the previously reported dose-dependent lowering of HTT protein and dose-dependent trends across clinical scales.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44538151/european-commission-declines-to-renew-marketing-authorization-of-translarna-duchenne-muscular-disorder" rel="noreferrer noopener">European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder</a>
&#8220;We look forward to discussions on the next development and regulatory steps, including the potential for accelerated approval as we work to potentially bring the first disease-modifying therapy&#8230;,&#8221; said&nbsp;Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics.
Results from the full 12-month cohort demonstrate dose-dependent lowering in blood HTT levels, with 23% at the 5mg dose level for both Stage 2 and 3 patients and 39% and 36% at the 10mg dose level for Stage 2 and 3 patients, respectively. For Stage 2 patients, there were dose-dependent trends of benefit on clinical scales, including the Composite Unified Huntington&#8217;s Disease Rating Scale (cUHDRS) and Total Motor Score (TMS) subscale.
For Stage 3 patients, trends favored the 5mg dose group relative to placebo but not the 10mg dose group, suggesting that treatment effect may differ in Stage 3 patients relative to Stage 2 patients. It seems investors are reacting to this as the stock is trading almost 20% lower during the premarket session.
PTC518 showed a favorable safety and tolerability profile for all dose levels and disease stages with no treatment-related serious adverse events or neurofilament light chain protein&nbsp;(NfL) spikes.
In addition, 24-month treatment data from the patients on whom data were shared last year (N=21) demonstrate signals of dose-dependent trends on the cUHDRS, Total Function Capacity (TFC), and Symbol Digit Modalities Test (SDMT) subscales when compared to a propensity-matched natural history cohort from the ENROLL-HD Registry.
At Month 24, there was also a dose-dependent lowering of plasma NfL from a baseline of -8.9% (nominal p=0.12) for the 5mg dose level and -14% (nominal p=0.03) for the 10mg dose level.
In April, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the marketing authorization application for Sephience (sepiapterin) for phenylketonuria (PKU). The opinion includes a broad label that includes <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45007096/ptc-therapeutics-receives-positive-chmp-opinion-for-sephience-sepiapterin-for-the-treatment-of-chi" rel="noreferrer noopener">all ages and disease severities</a>.
Price Action: PTCT stock fell 18.60% to $40.65&nbsp;on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45192411/netflix-stock-drops-as-trumps-proposed-tariffs-on-foreign-films-spark-concerns" target="_blank" rel="noreferrer noopener">Netflix And Other Streaming Stocks Slide As Trump&#8217;s Proposed Tariffs On Foreign Films Sparks Concern</a></li>
</ul>

Health Care

Movers

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock moved upwards by 52.8% to $0.7 during Monday's regular session. The company's market cap stands at $4.2 million. </li>
<li>Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) stock moved upwards by 35.6% to $2.32. The market value of their outstanding shares is at $337.2 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) stock moved upwards by 33.33% to $2.4. The company's market cap stands at $11.8 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 31.91% to $80.8. The company's market cap stands at $1.0 billion. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares rose 23.54% to $4.25. The company's market cap stands at $62.9 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 23.2% to $0.31. The market value of their outstanding shares is at $4.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) stock decreased by 26.4% to $12.4 during Monday's regular session. The company's market cap stands at $957.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares decreased by 23.47% to $1.37. The market value of their outstanding shares is at $18.2 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares declined by 22.46% to $0.58. The market value of their outstanding shares is at $6.6 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock fell 21.2% to $2.38. The market value of their outstanding shares is at $139.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) stock declined by 19.49% to $2.04. The market value of their outstanding shares is at $1.8 billion. </li>
<li>PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) stock declined by 17.48% to $41.22. The market value of their outstanding shares is at $3.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CYCC

IART

IBRX

IMMP

NCNA

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.2% on Monday.
The Dow traded up 0.21% to 41,406.25 while the NASDAQ fell 0.41% to 17,903.64. The S&amp;P 500 also fell, dropping, 0.26% to 5,671.90.
Check This Out: <a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a>
Leading and Lagging Sectors Industrials shares rose by 0.2% on Monday.
In trading on Monday, energy stocks dipped by 1.9%.
Top Headline
The ISM services PMI rose to 51.6 in April versus a nine-month low level of 50.8 in the previous month March and topping market estimates of 50.6.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Hyperscale Data, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NASDAQ">GPUS</a>) shares shot up 202% to $4.14 after the company issued first-quarter and FY25 sales guidance.</li>
<li>Shares of Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) got a boost, surging 25% to $61.70 after the company agreed to be acquired by 3G Capital for $63 per share.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) shares were also up, gaining 12% to $10.01 after the company reported a first-quarter sales beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) shares dropped 29% to $11.94 after the company reported a first-quarter adjusted EPS miss and cut its FY25 adjusted EPS guidance.</li>
<li>Shares of PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) were down 18% to $40.87. The company announced results from the Phase 2 PIVOT-HD study of PTC518 in Stage 2 and Stage 3 Huntington&#8217;s disease patients.</li>
<li>TG Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) was down, falling 16% to $36.53 after the company reported worse-than-expected first-quarter EPS results.</li>
</ul>
Commodities In commodity news, oil traded down 2.2% to $57.00 while gold traded up 2.5% at $3,323.40.
Silver traded up 0.6% to $32.455 on Monday, while copper rose 0.3% to $4.6875.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.06%, while Spain's IBEX 35 Index gained 0.40%. Germany's DAX 40 rose 0.87% and France's CAC 40 fell 0.58% during the session.
Asia Pacific Markets
Asian markets closed higher on Monday, with India's BSE Sensex rising 0.37%.
Economics
<ul>
<li>The S&amp;P Global services PMI was revised lower to 50.8 in April 2025 compared to a preliminary reading of 51.4.</li>
<li>The ISM services PMI rose to 51.6 in April versus a nine-month low level of 50.8 in the previous month March and topping market estimates of 50.6.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45192437/how-to-earn-500-a-month-from-williams-companies-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Williams Companies Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Intraday Update

BCRX

GPUS

TGTX

Crude Oil Falls Over 2%; ISM Services PMI Rises In April

PTC Therapeutics shares are trading lower. The company announced results from the Phase 2 PIVOT-HD study of PTC518 in Stage 2 and Stage 3 Huntington's disease patients.

Study met primary endpoint with dose-dependent blood HTT protein lowering at Week 12 -
- Favorable dose-dependent trends across clinical scales in Stage 2 patients at Month 12 -
- Signals of dose-dependent clinical benefit relative to matched natural history cohort as well as dose-dependent lowering of&nbsp;NfL in Stage 2 patients at Month 24 -
- Continued favorable safety and tolerability profile with no treatment-related NfL spikes -
- PTC will host a conference call on May 5, 2025, at 8:00 am ET-
&nbsp;PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) today announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients. The study met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels (p&lt;0.0001) at Week 12 and favorable safety and tolerability. In addition, the 12-month data from the Stage 2 patients are consistent with the previously reported dose-dependent lowering of HTT protein and dose-dependent trends across clinical scales.
"These PIVOT-HD results confirm that PTC518 lowers Huntingtin protein and shows early signals of clinical benefit with a favorable safety profile," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics. "In addition, at 24 months, we observed favorable dose-dependent trends on the cUHDRS and the TFC and SDMT subscales relative to natural history as well as dose-dependent lowering of neurofilament light chain protein. We look forward to discussions on the next development and regulatory steps including the potential for accelerated approval as we work to potentially bring the first disease-modifying therapy to those affected by Huntington's disease."

Ptc Therapeutics Announces Results From The Phase 2 Pivot-Hd Study of PTC518 In Stage 2 And Stage 3 Huntington's Disease Patients Study Met Its Primary Endpoint of Reduction in Blood Huntingtin Protein Levels At Week 12 And Favorable Safety and Tolerability

Press Releases

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results

PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

PTC518 PIVOT-HD Study Achieves Primary Endpoint

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

Comments

PTC Therapeutics

Notizie

Ultime notizie per PTC Therapeutics (NASDAQ:PTCT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO